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Abstract
Purpose To investigate men’s experiences of receiving external-beam radiotherapy (EBRT) with neoadjuvant Androgen 
Deprivation Therapy (ADT) for localized prostate cancer (LPCa) in the ProtecT trial.
Methods A longitudinal qualitative interview study was embedded in the ProtecT RCT. Sixteen men with clinically LPCa 
who underwent EBRT in ProtecT were purposively sampled to include a range of socio-demographic and clinical charac-
teristics. They participated in serial in-depth qualitative interviews for up to 8 years post-treatment, exploring experiences 
of treatment and its side effects over time.
Results Men experienced bowel, sexual, and urinary side effects, mostly in the short term but some persisted and were bother-
some. Most men downplayed the impacts, voicing expectations of age-related decline, and normalizing these changes. There 
was some reticence to seek help, with men prioritizing their relationships and overall health and well-being over returning 
to pretreatment levels of function. Some unmet needs with regard to information about treatment schedules and side effects 
were reported, particularly among men with continuing functional symptoms.
Conclusions These findings reinforce the importance of providing universal clear, concise, and timely information and sup-
portive resources in the short term, and more targeted and detailed information and care in the longer term to maintain and 
improve treatment experiences for men undergoing EBRT.
Keywords Prostate cancer · Radiotherapy · External-beam radiotherapy · Treatment experiences · Treatment side effects · 
Qualitative research
Introduction
Prostate cancer (PCa) is the most common cancer in males 
in the UK with 47,151 cases diagnosed in 2015 [1]. Ran-
domized controlled trials (RCTs) evaluating treatment 
options for clinically localized PCa (LPCa) have most often 
evaluated radical surgery and conservative management with 
frequent monitoring of the disease (e.g., active surveillance, 
active monitoring) [2, 3]. However, men may also receive 
external-beam radiotherapy (EBRT). Observational studies 
have shown that EBRT and brachytherapy have concomi-
tant risks of bowel, sexual, and urinary dysfunction [4, 5]. 
The prostate testing for cancer and treatment (ProtecT) RCT 
compared radical prostatectomy (RP), EBRT with neoad-
juvant androgen deprivation therapy (ADT), and active 
monitoring (AM) [6] and found very high survival rates 
and no evidence of differences in PCa or all-cause mortality 
between treatment groups after a median 10-year follow-up 
[6]. Patient-reported outcome measures (PROMs) showed 
that men allocated to EBRT reported higher levels of bowel 
dysfunction than the other groups, with erectile function 
affected particularly at six months. Urinary voiding and 
nocturia were worse in the EBRT group at 6 months, but 
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mostly recovered after 12 months and were then similar to 
other groups [7]. Quality of life related to functional symp-
toms mirrored these effects [7]. In this paper, we describe 
an investigation using qualitative methods undertaken to 
explore in detail individual men’s perspectives and experi-
ences of the EBRT treatment pathway.
Some previous qualitative studies have produced com-
bined findings for men receiving RP or EBRT, making it 
difficult to distinguish specific EBRT experiences [8–10]. 
Previous studies specifically focusing on EBRT [11–13] fol-
lowed up men between 6 weeks and one year only, finding 
unmet information needs regarding treatment options and 
side effects [11, 13], and some men feeling unsafe [13] or 
concerned about their ability to keep a full bladder during 
treatment [12]. The studies reported that many developed 
close relationships with the healthcare team because of the 
intensity and duration of treatment [11]. Men also reported 
‘normalization’ of sexual functioning within the context of 
growing older [12, 13].
The ProtecT qualitative study investigated men’s experi-
ences of receiving EBRT with neoadjuvant ADT for newly 
diagnosed LPCa from baseline up to eight years of follow-
up. The aims were to explore men’s experiences of treatment 
and its side effects over time, to provide contextual insights 
alongside the trial’s PROMs [7].
Subjects/patients (or materials) 
and methods
ProtecT study
The ProtecT RCT methods have been described in detail [6, 
14, 15]. Men declining randomization were offered identical 
follow-up and formed a comprehensive cohort within the 
study design [14]. ProtecT EBRT comprised neoadjuvant 
ADT for a minimum of three months and maximum of six 
months before and during 3-D conformal EBRT delivered at 
a dose of 74 Gy in 37 fractions [15]. This involved receiving 
hormone pellets injected into the stomach and attending a 
local oncology center every weekday for seven weeks. Men 
were asked to attend with a moderately full bladder and to 
empty the rectum of feces and flatus if possible. The analysis 
reported here was undertaken after 8 years of follow-up was 
completed to provide a longitudinal perspective.
Interview study
In-depth qualitative interviews explored men’s experi-
ences of treatment and related side effects [16]. The sam-
pling strategy for the qualitative interviews is described 
in detail elsewhere [15]. Sampling included men who 
were invited to take part in the interview study following 
diagnosis and decision-making about participation in the 
RCT, with serial interviews undertaken in a longitudinal 
design to explore men’s experiences over time [18]. Maxi-
mum variation sampling was used to include men from 
each treatment arm, those who accepted randomization 
or chose a treatment, older and younger men, a range of 
socioeconomic backgrounds, those with lower and higher-
risk cancer, from four of the nine study centers. This sam-
ple was augmented by a small number of men recruited 
prior to diagnosis and interviewed at points during the 
diagnosis process then at three yearly intervals following 
treatment [15]. Most interviews were conducted by JW; 
others by JD, LB, and LS (see acknowledgments) using 
the interview schedule in Table 1. Interviews were con-
ducted face-to-face in the man’s home, hospital outpatient 
department, or university premises, or by telephone and 
were audio-recorded. The first interviews of all but one of 
the men whose data are reported in the present study took 
place from 4 to 11 months post-EBRT (mean 8 months); 
subsequent interviews took place at around 2- to 3-year 
intervals facilitating exploration of perceived treatment 
outcomes and the impact of side effects over time. Inter-
view timings for individual men differed to take account of 
their treatment schedules and availability, with additional 
interviews if the research team became aware of major 
changes in the man’s treatment or disease. One man was 
recruited pre-diagnosis [15] and was interviewed both pre- 
and post-EBRT (Table 2). 
Written consent was obtained and participants were 
informed that they could withdraw from the study at any 
time. If men requested their partner to be present, they 
were invited to complete the same consent process. Four 
men included their partners in their first interview, but 
no partners were present for the following interviews. 
Interview recordings and field notes were reviewed by 
researchers conducting the interviews in order to develop 
follow-up interview questions, and analysis was carried 
out after all the data had been collected. Interviews were 
transcribed verbatim and data were analyzed thematically 
[19, 20] with the aid of NVivo software by ES and JW who 
met regularly to discuss the themes emerging from the 
data, comparing coding for a sample of transcripts, modi-
fying the coding framework, and developing recurring 
themes. Case studies for each participant were developed 
to enable us to track changes over time and explore how 
men adapted to their symptoms. A descriptive account 
was written up encompassing the interview themes. The 
researchers actively sought and discussed deviant cases to 
challenge the development of themes. Multicenter research 
ethics committee approval was obtained from the UK East 
Midlands (formerly Trent) Multicenter Research Ethics 
Committee (01/4/025).
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Results
Twenty-three men in the EBRT group were invited to par-
ticipate in qualitative interviews and 16 agreed to take 
part (3 did not respond, 3 refused, and 1 excluded as he 
did not have a telephone). Eleven had been randomized 
and 5 chose EBRT as their preferred treatment (Table 3). 
Most were interviewed at least three times at key points 
during treatment. Fourteen men participated in 3 inter-
views, 1 in 2 interviews (deceased), and 1 in 8 interviews 
(3 post-EBRT). Fifteen of the men were married at the 
time of the first interview and one divorced. Four main 
themes emerged: experiences of treatment, experiences 
and impact of treatment side effects, perceptions of out-
come, and reflections on information and support needs. 
Table 1  Interview topics
Introductions (including interviewer’s professional background, purpose, and length of interview and 
explanation of how confidentiality will be maintained)
• Decision-making whether to participate in the ProtecT study
• Experiences of the diagnostic process
• Impact of prostate cancer diagnosis at the time of diagnosis and ongoing
• Decision-making whether to accept random allocation to a treatment or to choose a treatment
• Views on radical treatments
• Expectations of HT/RT—including information provision
• Views and experiences of HT/RT to date
Impact of HT/RT
Any changes/improvements to RT treatment?
Experiences of ProtecT study participation
Second and third interviews explored
Experience of HT/RT since last contact, positive and negative
Ongoing impact of HT/RT
Reflections on treatment decision-making and any changes in views with time/events
Expectations of treatment vs outcomes
Experiences of living with PCa
Experiences of ProtecT study participation
Table 2  Men’s age at first interview and number of interviews
M married, D Divorced
Randomized to 
RT (Pseudonym)
Marital status Age at first 
interview
No of interviews
Ralph M 60–64 3
Derek M 55–59 3
Stephen M 65–69 3
Ray M 55–59 3
Len M 55–59 3
Alex M 65–69 3
Terrence M 65–69 3
Bernard M 60–64 3
Clive D 60–64 3
Donald M 64–69 3
Ned M 60–64 3
Chose RT
Ivor M 64–69 3
Geoff M 64–69 3
Keith M 60–64 2 (Deceased)
Alan M 60–64 3
Henry M 60–64 8 (3 post-RT)







 50–54 years 1 0
 55–59 years 2 1
 60–64 years 5 2










 Gleason 6, T1 7 3
 Higher grade or stage 4 2
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Each theme is reported below with quotations from men 
assigned pseudonyms to protect their identities. Additional 
quotations are presented in a Supplementary Table. Age at 
time of interview and length of time post-EBRT provide 
contextual information.
Experiences of treatment
Most men indicated that the EBRT pathway proceeded well 
and as expected. Several experienced temporary discomfort 
when receiving hormone injections, and the need to have a 
full bladder caused some anxiety:
The [hormone] injection was painful, but it’s bearable 
… after a half hour, pain was gone. (Alan, 63, 6m post 
RT)
One of the difficult things was having to sort of inflate 
your bladder with drinking a lot before the actual ses-
sion … that was fine if everything ran and generally it 
did … but if things overran then here you were bloated 
with all this liquid and dying to go to the loo. (Henry, 
62, 1y 10m post RT)
Many anticipated that 35 sessions of EBRT over 7 weeks 
would be arduous, but most were surprised at how easily it 
passed:
Thirty odd times I’ve had to go to there. Awful long 
time, but once you start doing it and you’re ticking off 
the days, you know, the weeks. It soon goes. (Ralph, 
70, 5y 10m post RT)
I was going to sleep on the bed, it was that relaxing. It 
didn’t feel as though I was fighting cancer. (Bernard, 
66, 5y 6m post RT)
Experiences and impact of the side effects 
of EBRT/ADT
All men reported experiencing some bowel, sexual, or uri-
nary side effects. Symptoms attributed to ADT included hot 
flushes, weight gain, breast enlargement and tiredness, some 
of which caused embarrassment:
They started me off on the hormone treatment in Sep-
tember … I’m still getting hot flushes … my wife 
laughs every time, because she says now you know 
what it’s like [laughs]. (Terrence, 67, 8m post RT)
I noticed the breast enlargement a bit as well, and 
that’s quite a bit … shocking … you think good God 
… what’s happening here? (Clive, 64, 4m post RT)
Problems with fatigue and disrupted sleep occurred and 
for some persisted, with men attributing this to various 
reasons including travel to hospital for treatment, age or 
comorbidities:
I’m perhaps slightly more tired than I was but that 
could be an age process anyway … I seem to sleep 
a lot … but it may be an element of age creeping 
on rather than the radiotherapy. (Henry, 62, 1y 10m 
post RT)
I also find now that I seem to be permanently tired. 
I don’t know whether that’s the anti- depressants 
because they can have that effect, or maybe it’s my 
approach to life. (Bernard, 66, 5y 6m post RT)
Most men reported bowel problems including urgency, 
loose motions/diarrhea, passing bloody mucus, or needing 
to strain, which, for some, persisted:
About 6 or 7 weeks … I was having problems with 
desperate sort of urgency and having to rush to the 
toilet. (Ned, 61, 6m post RT)
My toilet habits in the morning are a bit of a strain. I 
need to use the toilet three, sometimes four times of a 
morning before my day starts. (Derek, 62, 6y post RT)
Two men were diagnosed with radiation proctitis (inflam-
mation and damage to the colon after radiation exposure), 
causing severe and persisting problems:
I had a lot … a fair bit of pain and bleeding at one time 
… I sort of started getting over that and then I started 
getting some heavy bleeding from the back passage. 
(Stephen, 69, 2y 7m post RT)
It sort of flares up a couple of times a month … I get a 
bit of bolting pain in the stomach and I pass a mucus 
sort of deposit … and then it goes away and settles. 
(Alex, 70, 5y 4m post RT)
Urinary side effects were mostly not severe and reported 
at the first interview (4-12m post RT), including voiding, 
increased frequency, and some pain, although a few men 
experienced continuing issues, with nocturia contributing 
to fatigue:
There was a slight sort of stinging sensation for a while 
… it was there when you went you could sort of feel 
it, it was sort of acidic um sort of sensation. (Terrence, 
76, 8m post RT)
It’s very rare I have a night without having to get up. 
Usually only once, but sometimes it might be, you 
know, two or three times. (Ned, 64, 2y 11m post RT)
However, only three men sought prescribed medication 
for urinary symptoms:
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I went to the doctors and that helped a little bit just 
to realise that I wasn’t suffering on my own… it was 
just getting ridiculous. (Bernard, 66, 5y 6m post RT)
Most coped with urinary and bowel symptoms by being 
careful about what they drank, accommodating changes or 
being aware of the location of toilet facilities:
I decided that the stodge diet - bread, starchy foods - 
would be better than the healthy … five a day. (Ivor, 
69, 7m post RT)
So that’s the way I sort of plan it, my day… around 
the toilet. (Bernard, 63, 2y 9m post RT)
Difficulties with sexual function were common, with 
adverse impacts including lack of “sex drive” or desire, 
inability to maintain an erection or achieve a climax:
I don’t know with the radiotherapy, but the hormone 
treatment definitely affected my sex life [laughs]… 
instead of being ready and wanting to do it … it just 
takes it out of your mind almost. You’ve really got 
to say, you know, I haven’t had anything this week 
… almost force yourself to do it. (Terrence, 67, 8m 
post RT)
For some, there was recovery, but more reported anxi-
ety about its lack:
There was some problems with [sexual intercourse] 
during and after the treatment that’s sort of regular-
ised itself now after two years. (Donald, 71, 2y 9m 
post RT)
I have been waiting and waiting and waiting thinking 
it will come back, it will come back, it will come back 
and unfortunately it has not, or it does not appear to be 
coming back. I just wish I could get it fixed … why is 
it not gone back? Everything else appears to have gone 
back to the way it was. (Clive, 65, I yr, 8 mths post RT)
Treatments offered by clinical staff were helpful for some, 
but not used by others:
I did have trouble with my erection, I went onto tab-
lets but after so long everything has come right again. 
(Len, 60, 5y post RT)
I was offered Viagra. I think at one consultation with 
[urologist] he did give me a prescription for it, which 
I took to the dispensary and had tablets and I put them 
in a drawer and they’ve never been used. (Derek, 57, 
9m post RT)
Men delayed or rejected treatment or help-seeking for 
various reasons, including having a strong relationship, fam-
ily health issues, caring responsibilities, or waiting until they 
felt physically stronger:
We’ve been married fifty years and it’s not a problem 
for me and my wife … we’re happy as we are. (Ralph, 
70, 5y 10m post RT)
And like the nurse said, if we get any problems, just 
ring her and she’ll put a prescription down for me … 
but at the moment, you know I think my body’s had 
enough so give it a twelve month now give it a rest 
and see how it comes back then like. (Keith, 61, 11m 
post RT)
For those whose problems persisted in the longer term, 
it often became difficult to distinguish between the impact 
of comorbidities, normal aging, and treatment side effects. 
Many men expected that their sexual activity would decrease 
as they aged and general health became more important:
The most important thing for me is that is that I feel 
quite healthy so [the] sexual side of it is not over bur-
dening because I’ve been married for over 30 years … 
I probably would be more worried if I was in my 30s. 
(Ray, 61, 5y 5m post RT)
It doesn’t bother me very much because it’s more, it’s 
more of a sort of macho thing than anything else. It’s 
not that I’m in any sort of relationship or sort of look-
ing for any relationship it was more a case of you know 
what I mean, you feel old [laughs]. (Clive, 68, 4y 6m 
post RT)
Perceptions of outcome
Some men worried about follow-up test results and whether 
treatment had been successful:
The only question I keep asking myself is that, is it a 
cure? … I would like to think that I have been cured 
but what extent would it be, where I could say yes I’m 
cured, that’s the question… I would probably say at 
this present time that I’m living with it and with a few 
issues. (Ray, 61, 5y 5m post RT)
If you have the operation and have the prostate 
removed and that sort of thing then that’s done and 
dusted …. [with EBRT] I think it’s one these things 
where you can never be absolutely 100% certain that 
it’s gone. (Donald, 73, 4y 10m post RT)
In contrast, others considered their treatment complete, 
particularly if they experienced few side effects, with some 
comparing their experience to others they perceived as less 
fortunate:
When you’re told, you know, it’s a bit of a shock but 
… after you’ve had the treatment no problem at all. I 
was working up until the last week … I was getting 
 Cancer Causes & Control
1 3
very tired … I had a week off and then you’re back to 
normal. (Keith, 62, 1y 9m post RT)
I don’t feel as though I’ve had prostate cancer, com-
pared to the stories that you hear in the newspapers, 
friends and stuff like that. I still don’t feel as though 
I’ve had the full-blown thing. It’s like having a cold 
compared to pneumonia. (Bernard, 63, 2y 9m post RT)
Reflections on information/support needs
During interviews, participants reflected on the study infor-
mation sheet detailing potential side effects of treatment 
and leaflets provided by the local hospital. There were some 
aspects of timing and details of treatments they felt could 
be improved:
I think we waited three maybe four months for the 
radiotherapy to start, which whilst it wasn’t the end 
of the world, I wasn’t in pain or feeling ill, it did sort 
of mess my life up a bit if you like. Shall we go on 
holiday? ….. These [hormone] implants have to take 
time to work. That much wasn’t explained. (Derek, 57, 
9m post RT)
Lots of clicks and bangs. OK, I know that all the 
machinery makes a lot of noise … some people might 
appreciate the technical advice and other people, it 
might frighten them away. (Geoff, 67, 9 m post RT)
Those who experienced more or serious side effects felt 
they had not been sufficiently prepared – suggesting that 
information should be provided on an ongoing basis (not 
just at the start) to men who do experience such side effects:
I didn’t know very much about radiotherapy and the 
side-effects (Ned, 61, 6m post RT)
They could sit you down and talk to you more about 
what is going on, … what is likely to happen to you. 
(Stephen, 72, 4y 2m post RT) [And]
They tell you that there can be side-effects but … I 
wasn’t aware that was something you could get [radia-
tion proctitis] as bad as I did get (Stephen, 73, 5y 7m 
post RT)
However, many men described in positive terms the sup-
port and information they had received from healthcare pro-
fessionals and members of the ProtecT team:
I think the thing that really stands out is the help and 
support actually in the oncology through all my treat-
ment. I think that was just absolutely outstanding … 
It wasn’t one of these things, “Oh God, I’ve gotta go 
have radiotherapy tomorrow.” It was, I know it sounds 
ridiculous, but it was a pleasure to go there. Now that 
in itself was as good as the treatment. (Donald, 73, 4y 
10 m post RT)
Another important factor was the support they received 
from peers, friends, and family:
[A] group got together [at hospital] and started talk-
ing with one another … the best part of it was the fact 
that the group of people who were there, they weren’t 
frightened to talk to one another … it was good fun … 
eased the pressure off of everybody. (Alex, 65, 11m 
post RT)
Every time I went to [hospital] [wife] was with me … 
we used to make a little thing we’d either go down in 
the morning perhaps stop for lunch on the way back or 
do a little bit of shopping or something like that, and 
or friends would come with us so we used to make a 
bit of a day out. (Ralph, 65, 9m post RT)
Discussion
The findings reported here illustrate the ways that men 
organized their lives post-EBRT, developing coping strat-
egies to accommodate side effects that continued in the 
longer term and by getting on with their lives. For many, 
their narratives enabled post-EBRT changes to be normal-
ized and blurred together with expected age-related changes. 
They described the support they had received from clinical 
teams in glowing terms. However, there were some men who 
continued to worry about the outcome of their treatment 
or struggled with longer-term problems, such as radiation 
proctitis, or persisting issues with sexual function, for whom 
more information and care were needed.
These qualitative findings align with evidence from quan-
titative PROMS [7] but provide important additional con-
textual and experiential insights into men’s recovery. Men 
experienced a range of side effects on bowel, sexual, and uri-
nary function as well as hot flushes, weight gain, and fatigue 
attributed to ADT. They generally reported satisfaction with 
the care received, particularly valuing the support provided 
by health professionals and members of the ProtecT research 
team over the lengthy treatment period: a factor noted in 
previous studies [11, 21].
Men reported their experiences of the adverse impact 
of the side effects of EBRT and ADT on urinary, bowel, 
and sexual function. However, in contrast to the findings of 
previous research [8], rather than solely referring to age in 
relation to a loss of sexual function, the men in our study 
demonstrated adaptive preferences when discussing all these 
areas of impact, finding it difficult to unpick the effects of 
aging, comorbidities, and related treatment from the impact 
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of EBRT or ADT. As with other studies, a few men expe-
rienced difficulties in retaining a full bladder during EBRT 
treatment and temporary pain from hormone injections 
[12], but unlike Oster et al’s study [13], ProtecT men did 
not report feeling unsafe. A small number of men reported 
embarrassment with breast enlargement, and although some 
referred to the impact on their masculine identity [22], none 
reported directly avoiding intimacy [23, 24] and they were 
generally accepting of their post-treatment persona [13].
Men tended to downplay the impacts of treatment gen-
erally and there was reticence to seek help, particularly 
with regard to sexual function [10, 21] but also for urinary 
problems. Some exhibited temporalizing—waiting to see if 
things improved before seeking help [25]. Factors affect-
ing decisions to seek help included partner influence, fam-
ily health issues, caring responsibilities, and needing time 
to recover. Many men emphasized the importance of hav-
ing a strong relationship with their partner and prioritized 
recovery from PCa over returning to pretreatment levels 
of sexual function [9, 10, 12]. None of the men reported 
accessing psychosexual services but were provided with 
the opportunity to discuss sexual function problems with 
study nurses. Appropriate timing of information giving has 
been highlighted in previous research [26]. Some men in 
this study reported unmet needs with regard to information 
on treatment schedules and side effects of ADT and EBRT 
[21], particularly when they experienced more severe or 
longer-term symptoms. Men also highlighted the difficulties 
of interpreting follow-up test results and wanting to know 
whether their treatment was successful [10, 21], with uncer-
tainty impacting upon anxiety levels and coping capacity. 
Other men reported that life had reverted back to “normal” 
even while coping with persisting treatment impacts, align-
ing with narratives of a “new normal” reported by Baker 
et al. [27].
The importance of support from others echoed findings 
from previous studies [11, 13, 19, 24, 28], as did strategies of 
coping with bowel and urinary symptoms by changing fluid 
intake or being aware of the location of toilet facilities [13, 
29]. A few of the men also made downward comparisons 
referring to others they believed were less fortunate [30].
In comparison to the study PROMS where urinary func-
tion was function was mostly recovered at 12 months, a few 
men in our study reported longer-term urinary symptoms. It 
may be that the interviews gave the men greater opportuni-
ties to reflect on longer-term side effects in more detail. We 
found no notable differences in the experiences of men who 
were younger (50–59) or older (60–69) at diagnosis, or for 
those who were randomized to, or chose EBRT, or between 
those with low (Gleason 6) or intermediate (Gleason 7+) 
risk cancer.
Men in the randomized group were slightly more likely 
to report anxiety regarding the success of their treatment, 
although we recognize that, due to the modest number of 
men interviewed, in statistical terms, this may not reflect a 
difference in the study population as a whole.
This study has both strengths and limitations. Limitations 
of the study include that none of the study participants were 
from minority ethnic groups or identified themselves as gay 
or bisexual. The majority were married so we recognize that 
perceptions regarding body image and sexual function might 
differ amongst single men. A key strength is the data collec-
tion embedded within the ProtecT trial and three interviews 
conducted with most participants over 8 years of follow-up. 
This clearly contrasts with previous research with a maxi-
mum of 12 months of follow-up [12] and usually less [11, 
13]. A total of 47 interviews were conducted post-RT allow-
ing in-depth exploration of individual issues and providing 
evidence of how men’s narratives evolved over time.
Conclusions
This study has provided an in-depth insight into men’s expe-
riences of EBRT and neoadjuvant ADT, and the strategies 
employed to cope with these over the longer term, which 
add to the quantitative findings from the ProtecT trial. Some 
important gaps in information provision and support were 
found, particularly for men experiencing severe or longer-
term symptoms. Many of the symptoms relating to treatment 
side effects improved over time, although normalization and 
adaptation were evident in many accounts, leading to defer-
ral or failure to seek help. This needs to be considered when 
designing service and information provision, particularly 
with regard to impact on sexual function and related treat-
ments—regardless of patient age. The importance of support 
from health professionals, family, and peers was clear, but 
some men expressed anxiety regarding follow-up tests and 
not knowing if their treatment had been successful. These 
findings highlight the importance of providing clear, con-
cise, and timely information and supportive resources in the 
short term, and more targeted and detailed information and 
care in the longer term to maintain and improve treatment 
experiences for men undergoing EBRT.
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